Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Depreciation & Amortization (CF) (2018 - 2025)

TransMedics (TMDX) has 8 years of Depreciation & Amortization (CF) data on record, last reported at $7.5 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 31.48% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $27.2 million, up 37.59%, while the annual FY2025 figure was $27.2 million, 37.59% up from the prior year.
  • Depreciation & Amortization (CF) reached $7.5 million in Q4 2025 per TMDX's latest filing, up from $6.8 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $7.5 million in Q4 2025 and bottomed at $445000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.0 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): grew 8.37% in 2021, then surged 234.27% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $466000.0 in 2021, then soared by 175.75% to $1.3 million in 2022, then skyrocketed by 180.54% to $3.6 million in 2023, then soared by 57.56% to $5.7 million in 2024, then soared by 31.48% to $7.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $7.5 million in Q4 2025, $6.8 million in Q3 2025, and $6.7 million in Q2 2025.